Cargando…

Patient and Payer Preferences for Additional Value Criteria

Background: Defining the value of healthcare is an elusive target, and depends heavily on the decision context and stakeholders involved. Cost-utility analysis and the quality-adjusted life year (QALY) have become the method and value definition of choice for traditional value judgements in coverage...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jakab, Ivett, Whittington, Melanie D., Franklin, Elizabeth, Raiola, Susan, Campbell, Jonathan D., Kaló, Zoltán, McQueen, R. Brett
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263917/ https://www.ncbi.nlm.nih.gov/pubmed/34248638 http://dx.doi.org/10.3389/fphar.2021.690021

Ejemplares similares

Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countries—A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses
por: Jakab, Ivett, et al.
Publicado: (2020)

Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods
por: McQueen, R. Brett, et al.
Publicado: (2022)

Achieving high value care for all and the perverse incentives of 340B price agreements
por: Whittington, Melanie D., et al.
Publicado: (2018)

Proposal for capturing patient experience through extended value frameworks of health technologies
por: Inotai, András, et al.
Publicado: (2021)

Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways
por: Ermisch, Michael, et al.
Publicado: (2016)

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation
por: Vella Bonanno, Patricia, et al.
Publicado: (2017)

Incremental cost of premature birth – a public health care payer perspective from Hungary
por: Kovács, Gábor, et al.
Publicado: (2023)

Variability in Private Payer Medical Policies for Osteochondral Allograft Transplantation Demonstrates the Absence of Standardization in Medical Criteria Between Payers
por: Tabbaa, Suzanne M., et al.
Publicado: (2022)

The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Synnott, Patricia G., et al.
Publicado: (2020)

Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis
por: Kolasa, Katarzyna, et al.
Publicado: (2018)

MON-306 Acromegaly Comorbidity Costs, Quality of Life, and Mortality: Lifetime Comparisons for Controlled Acromegaly, Uncontrolled Acromegaly, and the General US Population
por: Whittington, Melanie D, et al.
Publicado: (2020)

Implementation of Health Technology Assessment in the Middle East and North Africa: Comparison Between the Current and Preferred Status
por: Fasseeh, Ahmad, et al.
Publicado: (2020)

Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States
por: Carlson, Josh J., et al.
Publicado: (2019)

How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia
por: Tesar, Tomas, et al.
Publicado: (2019)

Recommendation for a Pilot MCDA Tool to Support the Value-Based Purchasing of Generic Medicines in the UAE
por: Farghaly, Mohamed Naser, et al.
Publicado: (2021)

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
por: Wang, Ting, et al.
Publicado: (2022)

Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment
por: McQueen, R. Brett, et al.
Publicado: (2021)

Expanding the Role of the Patient-Centered Outcomes Research Institute: Reauthorization and Facilitating Value Assessments
por: Padula, William V., et al.
Publicado: (2019)

Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer
por: Tesar, Tomas, et al.
Publicado: (2017)

Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma
por: Whittington, Melanie D., et al.
Publicado: (2019)

Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States
por: Mendola, Nicholas D, et al.
Publicado: (2022)

Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications
por: Incze, András, et al.
Publicado: (2022)

Overview on Patient Centricity in Cancer Care
por: Narbutas, Šarunas, et al.
Publicado: (2017)

Payer perceptions and use of value assessment tools in the United States
por: Westrich, Kimberly, et al.
Publicado: (2023)

Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years
por: Mela, Aneta, et al.
Publicado: (2020)

Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment
por: Dhanda, Devender S., et al.
Publicado: (2020)

Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US
por: Whichello, Chiara, et al.
Publicado: (2019)

Hospitals and the Tax-Payer
Publicado: (1920)

Potentially inappropriate medications in older Chinese outpatients based on the Beers criteria and Chinese criteria
por: Zhang, Ying, et al.
Publicado: (2022)

Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts
por: Kannarkat, Joseph T., et al.
Publicado: (2020)

Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries
por: Dimitrova, Maria, et al.
Publicado: (2022)

Reconstructing the value puzzle in health technology assessment: a pragmatic review to determine which modelling methods can account for additional value elements
por: Muir, Jeffrey M., et al.
Publicado: (2023)

Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries
por: Zelei, Tamás, et al.
Publicado: (2016)

Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries
por: Inotai, András, et al.
Publicado: (2020)

Values-Based Foundation for a U.S. Single Payer Health System Model
por: Markowitz, Walter, et al.
Publicado: (2021)

A Private Payer Persective
por: Shurney, Dexter W.
Publicado: (2006)

The effectiveness and value of tezepelumab for severe asthma: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Rind, David M, et al.
Publicado: (2022)

Pharmaceutical Technology Assessment: Perspectives from Payers
por: Leung, Musetta Y., et al.
Publicado: (2012)

Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs
por: Kolasa, Katarzyna, et al.
Publicado: (2016)

Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine?
por: Akhmetov, Ildar, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_me7jb80fjc0ehq0qq7b54pt4du